Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Liu, Pengcheng; Cai, Jiehao; Jia, Ran; Xia, Shuai; Wang, Xiangshi; Cao, Lingfeng; Zeng, Mei; Xu, Jin
• Is Part Of: Emerging microbes & infections. Volume 9:Issue 1(2020)
• Page Start: 1254
• Page End: 1258
• Publication Date: 2020-01-01
• Subjects: Children -- SARS-CoV-2 -- COVID-19 -- viral shedding -- neutralizing antibody; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2020.1772677
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and quickly spread globally. In this study, we investigated the characteristics of viral shedding from different sites and the neutralizing antibody (NAb) response during the acute and convalescent phases of nine children with COVID-19. SARS-CoV-2 was detected in their nasopharyngeal swabs (9/9, 100%), stool samples (8/9, 89%), and oropharyngeal swabs (3/9, 33%) but was not detected in their serum and urine samples. The median duration of viral shedding detected in nasopharyngeal swabs, oropharyngeal swabs, and stools was 13, 4, and 43 days respectively, and the maximum duration of viral shedding detected from stools was 46 days after discharge. In children, nasopharyngeal swabs appear to be a more sensitive specimen type for the diagnosis of COVID-19 compared with oropharyngeal swabs. Three of eight patients produced NAbs in the acute phase, and NAbs were detected in all eight patients with convalescent sera. The results of this study provide valuable information for the diagnosis and surveillance of COVID-19 and development of SARS-CoV-2 vaccines for use in children.